James Kilts - Pfizer Independent Director

PFE
 Stock
  

USD 51.72  0.06  0.12%   

  Director
Mr. James Marshall Kilts is an Independent Director of Pfizer Inc., since September 27, 2007. He is Founding Partner, Centerview Capital, a private equity firm, since 2006. Vice Chairman, The Procter Gamble Company, from 2005 to 2006. Chairman and Chief Executive Officer, The Gillette Company, from 2001 to 2005 and President, Gillette, from 2003 to 2005. President and Chief Executive Officer, Nabisco Group Holdings Corporationrationration, from 1998 until its acquisition in 2000. NonExecutive Director of the Board of Nielsen Holdings PLC, Chairman of the Board of Nielsen Holdings and Chairman of the Nielsen Company B.V. . Executive Chairman of the Board of Conyers Park Acquisition Corporationrationration . Director of MetLife, Inc. and Unifi, Inc. . Chairman of Big Heart Pet Brands until March 2015 and Director of Meadwestvaco Corporationrationration until April 2014. Life Trustee of Knox College and Trustee of the University of Chicago, a member of the Board of Overseers of Weill Cornell Medicine, and Founder and CoChair, Steering Committee, of the Kilts Center for Marketing at the University of Chicago Booth School of Business. his tenure as CEO of Gillette and Nabisco and as Vice Chairman of Procter Gamble provides valuable business, leadership and management experience, including expertise in cost management, value creation and resource allocation. In addition, his knowledge of consumer businesses has given him insights into reaching consumers and the importance of innovationboth important aspects of Pfizers business. Through his service on various compensation committees, including ours, Mr. Kilts has a strong understanding of executive compensation and related areas. Through his service on the board of MetLife, Inc., an insurance company, Mr. Kilts offers a view of healthcare from another perspective.
Age: 71  Director Since 2007      
212 733 2323  https://www.pfizer.com

Pfizer Management Efficiency

Pfizer Inc has Return on Asset of 0.1332 % which means that on every $100 spent on asset, it made $0.1332 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.3551 %, implying that it generated $0.3551 on every 100 dollars invested. Pfizer management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Pfizer Return on Average Assets are projected to increase based on the last few years of reporting. The past year's Return on Average Assets were at 13.09. The current year Return on Average Equity is expected to grow to 33.77, whereas Return on Invested Capital is forecasted to decline to 0.22. Pfizer Current Assets are projected to decrease significantly based on the last few years of reporting. The past year's Current Assets were at 59.69 Billion. The current year Tax Assets is expected to grow to about 5.8 B, whereas Goodwill and Intangible Assets are forecasted to decline to about 84.3 B.
The company has 36.2 B in debt with debt to equity (D/E) ratio of 0.4, which is OK given its current industry classification. Pfizer Inc has a current ratio of 1.56, which is typical for the industry and considered as normal. Debt can assist Pfizer until it has trouble settling it off, either with new capital or with free cash flow. So, Pfizer's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pfizer Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pfizer to invest in growth at high rates of return. When we think about Pfizer's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Frederick McNabbInternational Business Machines
2019
Darius AdamczykJohnson Johnson
2022
Michael BoskinExxon Mobil Corp
1996
Kathryn FullerAlcoa Corp
2016
Aylwin LewisWalt Disney
N/A
Lionel NowellBank Of America
2021
Melanie HealeyVerizon Communications
2011
William PerezJohnson Johnson
2007
Anne MulcahyJohnson Johnson
2012
Eugene WashingtonJohnson Johnson
2012
Arne SorensonMicrosoft
2017
John ChenWalt Disney
N/A
Suzanne SitherwoodAlcoa Corp
2016
Michelle HowardInternational Business Machines
2019
Sheryl SandbergWalt Disney
2010
Marillyn HewsonJohnson Johnson
2019
Richard RexachVerizon Communications
1997
William WeldonExxon Mobil Corp
2013
Hutham OlayanInternational Business Machines
2016
Ken NewmanWalt Disney
2019
Ursula BurnsExxon Mobil Corp
2012
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 79000 people. Pfizer Inc (PFE) is traded on New York Stock Exchange in USA and employs 79,000 people. Pfizer is listed under Pharmaceuticals category by Fama And French industry classification.

Pfizer Inc Leadership Team

Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller
Douglas Lankler, Executive Vice President General Counsel
Shantanu Narayen, Lead Independent Director
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical
Susan DesmondHellmann, Independent Director
Stephen Sanger, Independent Director
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer
Aamir Malik, Executive Vice President Chief Business Innovation Officer
Christopher Stevo, Senior Vice President and Chief Investor Relations Officer
Geno Germano, Group President of Global Innovative Pharma Bus.
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
William Carapezzi, Executive Vice President - Global Business Services and Transformation
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President
Mikael MD, Dev Research
James Quincey, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Payal Sahni, Executive Vice President, Chief People Experience Officer
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President - Pfizer Biopharmaceuticals Group
Mike Mcdermott, Executive Vice President Chief Global Supply Officer
Kathrin Jansen, Senior Vice President - Vaccine Research & Development
John Young, Group President - Pfizer Innovative Health and Angela Hwang
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
James Smith, Independent Director
Christopher CFA, VP Officer
Dennis Ausiello, Independent Director
Michael Mcdermott, Executive Vice President Chief Global Supply Officer
Frances Fergusson, Independent Director
Gordon Loh, Senior Vice President Corporate Audit
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
David Denton, Chief VP
Alexander Mackenzie, Executive Vice President Chief Development Officer
DVM DVM, Chairman CEO
William Gray, Independent Director
Sally Susman, Chief Corporate Affairs Officer, Executive Vice President
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Susan Hockfield, Independent Director
Freda LewisHall, Executive Vice President Chief Medical Officer
Dan Littman, Independent Director
Ian Read, Chairman, CEO and Chairman of Executive Committee
James Kilts, Independent Director
Don Cornwell, Independent Director
Joseph Echevarria, Independent Director
Scott Gottlieb, Independent Director
Ronald Blaylock, Independent Director
Michael Goettler, Group President - Pfizer Upjohn

Pfizer Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pfizer Investors Sentiment

The influence of Pfizer's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Pfizer. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Pfizer's public news can be used to forecast risks associated with investment in Pfizer. The trend in average sentiment can be used to explain how an investor holding Pfizer can time the market purely based on public headlines and social activities around Pfizer Inc. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Pfizer's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Pfizer's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Pfizer's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Pfizer.

Pfizer Implied Volatility

    
  35.1  
Pfizer's implied volatility exposes the market's sentiment of Pfizer Inc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Pfizer's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Pfizer stock will not fluctuate a lot when Pfizer's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pfizer in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pfizer's short interest history, or implied volatility extrapolated from Pfizer options trading.

Currently Active Assets on Macroaxis

Please check Your Equity Center. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Pfizer Stock analysis

When running Pfizer Inc price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.055
Market Capitalization
290.7 B
Quarterly Revenue Growth YOY
(0.06) 
Return On Assets
0.1332
Return On Equity
0.3551
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine Pfizer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.